Dana Boyle Biography and Net Worth

CAO of Liquidia

Dana Boyle joined Liquidia in 2021 where she serves as Senior Vice President, Controller. With approximately 20 years of experience, Dana brings deep knowledge in accounting, financial planning and analysis, and business operations to her role at Liquidia. Previously, Dana held progressive financial roles at various startups and mid-sized life-science companies including Aerami Therapeutics, Aralez Pharmaceuticals and Iveric Bio. She began her career in Audit & Assurance and Mergers & Acquisitions Transaction Services at Deloitte. Dana holds a Bachelor of Science in accounting from Rutgers University and is a CPA licensed in the state of New York.

What is Dana Boyle's net worth?: The estimated net worth of Dana Boyle is at least $5.26 million as of December 1st, 2025. Ms. Boyle owns 155,031 shares of Liquidia stock worth more than $5,258,652 as of December 4th. This net worth estimate does not reflect any other assets that Ms. Boyle may own. Learn More about Dana Boyle's net worth.
How do I contact Dana Boyle?: The corporate mailing address for Ms. Boyle and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at [email protected]. Learn More on Dana Boyle's contact information.
Has Dana Boyle been buying or selling shares of Liquidia?: Over the course of the past ninety days, Dana Boyle has sold $63,339.04 in Liquidia stock. Most recently, Dana Boyle sold 303 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $32.19, for a transaction totalling $9,753.57. Following the completion of the sale, the chief accounting officer now directly owns 155,031 shares of the company's stock, valued at $4,990,447.89. Learn More on Dana Boyle's trading history.
Who are Liquidia's active insiders?: Liquidia's insider roster includes Jason Adair (Chief Business Officer), Dana Boyle (CAO), Roger Jeffs (CEO), Michael Kaseta (CFO), Arthur Kirsch (Director), Sarah Krepp (Insider), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), Rajeev Saggar (Insider), Russell Schundler (General Counsel), and Raman Singh (Director). Learn More on Liquidia's active insiders.
Are insiders buying or selling shares of Liquidia?: In the last year, insiders at the sold shares 52 times. They sold a total of 1,155,124 shares worth more than $29,483,872.80. The most recent insider tranaction occured on December, 1st when General Counsel Russell Schundler sold 1,072 shares worth more than $34,507.68. Insiders at Liquidia own 26.5% of the company. Learn More about insider trades at Liquidia.
Information on this page was last updated on 12/1/2025.

Dana Boyle Insider Trading History at Liquidia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2025	Sell	303	$32.19	$9,753.57	155,031
10/27/2025	Sell	1,073	$22.93	$24,603.89	184,338
10/13/2025	Sell	1,238	$23.41	$28,981.58	185,411
7/28/2025	Sell	1,063	$19.54	$20,771.02	186,105
7/14/2025	Sell	1,193	$14.28	$17,036.04	187,168

Dana Boyle Buying and Selling Activity at Liquidia

Liquidia Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Today's Range

Now: $33.92

$33.00

$34.08

50 Day Range

MA: $26.04

$21.80

$33.92

2 Week Range

Now: $33.92

$10.37

$34.08

Volume

880,832 shs

Average Volume

1,935,568 shs

Market Capitalization

$2.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48